
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Safety of Intrathecal Riluzole in Patients with Amyotrophic Lateral Sclerosis
Details : Riluzole is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 30, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Riluzole
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Brain Trust Receives Approval for Trials Targeting CNS Diseases with Intrathecal Delivery
Details : IT Riluzole (riluzole)is a intrathecally delivered glutamate antagonist. It is being evaluated for the treatment of amyotrophic lateral sclerosis & other central nervous system diseases.
Product Name : IT-Riluzole
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : Riluzole
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
